research Safety Evaluation of Topical Valproate Application
Topical Valproate is safe for human skin and unlikely to cause irritation.
Search
for
Sort by
Research
420-450 / 1000+ results 
research Topical 15% Lactic Acid Solution versus Topical Betamethasone Valerate lotion in Treatment of Multiple patchy alopecia aerate.
Betamethasone valerate lotion is more effective for treating multiple patchy alopecia areata.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research P.1.g.019 RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity
RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Anti-anginal and beta-adrenoceptor blocking drugs
Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
research Glucocorticoids and Risk of Venous Thromboembolism in Asthma Patients Aged 20–59 Years in the United Kingdom’s CPRD 1995–2015
Higher doses of glucocorticoids increase the risk of blood clots in asthma patients.
research Influence of an iplatelant therapy with P2Y12 receptor inhibitors on platelet function in elderly patients with acute coronary syndrome
Ticagrelor works better than clopidogrel in reducing platelet activity in elderly patients with acute coronary syndrome.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
Topical calcitriol is safe for preventing hair loss during chemotherapy.
research Alopecia associated with atorvastatin
Atorvastatin may cause hair loss in some people.
research Valproate-induced change in hair color
Valproic acid can cause hair loss, but information on hair color change is not detailed.
research Betamethasone valerate/minoxidil/tretinoin
The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
research Case Report: Analytically Confirmed Severe Albenzadole Overdose Presenting with Alopecia and Pancytopenia
Overdosing on veterinary albendazole can cause severe health issues like hair loss and low blood cell count.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol
Testosterone increases seizure risk through its conversion to specific neurosteroids.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research PSAT097 Patient Preference Research: Preferred Adjunctive Medication Attributes of Adult Patients with Classic Congenital Adrenal Hyperplasia
Adults with classic congenital adrenal hyperplasia value medication that prevents weight gain from glucocorticoids the most.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research Local Changes in Neurosteroid Levels in the Substantia Nigra Reticulata and the Ventral Tegmental Area Alter Chronic Ethanol Withdrawal Severity in Male Withdrawal Seizure‐Prone Mice
Ethanol withdrawal reduces the brain's response to certain calming steroids, making seizures harder to control.
research Topical use of calcipotriol does not potentiate squaric acid dibutylester effectiveness in the treatment of alopecia areata
Calcipotriol does not improve the effectiveness of squaric acid dibutylester in treating alopecia areata.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting
Finasteride may help reduce impulsivity caused by pramipexole.
research Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for long-term use in treating alopecia areata.
research Role of allopregnanolone biosynthesis in acute stress-induced anxiety-like behaviors in mice
Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.
research Finasteride/hypericum interaction
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.